Carbomer 974P ( DrugBank: Carbomer 974P, Carbomer )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
53シェーグレン症候群1

53. シェーグレン症候群


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-001708-19-FR
(EUCTR)
23/08/200706/08/2007A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial.A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial. treatment on bilateral moderate dry eye syndrome due to Sjögren's syndrome or diagnosed as a primary syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10013774;Term: Dry eye
Product Name: SVS20
Product Code: SVS20
INN or Proposed INN: sodium hyaluronate
Trade Name: Lacryvisc
INN or Proposed INN: carbomer 974P
Product Name: SALINE
INN or Proposed INN: sodium chloride
TRB CHEMEDICA INTERNATIONAL SANULLNot RecruitingFemale: yes
Male: yes
300Phase 3France;United Kingdom